Pipeline click the colored bars to visit the associated page.

PROGRAM

 
EARLY
PRE-CLINICAL
 
LATE
PRE-CLINICAL
 
PHASE 1

 
PHASE 2

 
IMMUNO-ONCOLOGY

CHEMOTHERAPEUTICS
NPG-114
pEGR1-CYTOKINE 1-DNA-pep/NPs

NPG’s NanoPro™ for immuno-oncology delivers cytokines specifically/selectively into tumor cells. The efficacy of DNA delivery is often limited because very small fractions of the administered DNA accumulates in tumors. NPG has developed novel and unique nanoparticles (NPs) that overcome multiple biological barriers to deliver DNA into the nucleus with a radiation sensitive promoter thus allowing cytokine production by the tumor itself and causing the tumor to self-destruct.

Cytokine 1 is a well-known anti-cancer cytokine and works synergistically with the new pipeline of immunotherapies including the PD-1/PDL-1 antibodies.


NPG-384 (Nanoxane™)
Paclitaxel encapsulated in NanoPro™ nanoparticles for the treatment of Paclitaxel/Abraxane®-resistant metastatic breast cancer

Tetra-block nanoparticles encapsulating paclitaxel (Nanoxane™) generated using our proprietary NanoPro™ technology are stealth, long circulating and have a superior pharmacokinetic profile compared to Abraxane®or Genexol-PM (Cynviloq™ in the USA acquired by Nantworks, Inc. for up to $1.3 Billion). The disintegration of nanoparticles and release of paclitaxel from Nanoxane™ is much slower compared to these Abraxane® or Genexol-PM/Cynviloq™.

Paclitaxel/Abraxane®-resistant metastatic breast cancer is an orphan, unmet need. Eventually most patients become resistant to Paclitaxel treated-metastatic breast cancers.